{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Harrow, Inc. Hits Day High with 12.6% Surge in Stock Price
Harrow, Inc., a small-cap pharmaceutical company, experienced notable stock activity, reaching an intraday high. Despite a year-over-year decline, the company has shown positive year-to-date performance and significant growth in net sales and profits. Strong institutional holdings reflect investor confidence in its fundamentals.
Harrow, Inc. Hits Day High with 13.47% Surge in Stock Price
Harrow, Inc. has seen a notable increase in its stock price, reaching an intraday high amid strong market activity. The company reported a significant rise in net sales and impressive quarterly profits, alongside high institutional holdings, reflecting strong investor confidence and long-term growth potential.
Harrow, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators
Harrow, Inc., a small-cap pharmaceutical company, has experienced notable stock fluctuations, currently priced at $38.52. The company has shown impressive long-term growth, with significant returns over three, five, and ten years, outperforming the S&P 500. Technical indicators present a mixed performance outlook.
Harrow, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators
Harrow, Inc., a small-cap pharmaceutical company, has seen its stock price rise recently, despite a year-over-year decline. The company has shown resilience with a positive year-to-date return, outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting volatility in market sentiment. Harrow's five-year performance significantly exceeds that of the S&P 500.
Is Harrow, Inc. technically bullish or bearish?
As of October 10, 2025, Harrow, Inc. shows a mildly bullish trend with positive weekly indicators, a year-to-date return of 15.56% outperforming the S&P 500, but a yearly return of -23.55% underperforming the index.
Is Harrow, Inc. technically bullish or bearish?
As of October 10, 2025, Harrow, Inc. shows a mildly bullish technical trend despite recent underperformance compared to the S&P 500, with a 3-year return of 210.26% and a 5-year return of 561.02%.
Is Harrow, Inc. technically bullish or bearish?
As of October 10, 2025, Harrow, Inc. shows a mildly bullish trend supported by various indicators, despite recent underperformance against the S&P 500 over the short term, while outperforming it year-to-date and over the longer three and five-year periods.
Harrow, Inc. Hits Day Low of $41.03 Amid Price Pressure
Harrow, Inc. faced a significant stock decline today, reaching an intraday low. Over the past week, the company has struggled, contrasting with the S&P 500's performance. However, year-to-date, Harrow has outperformed the index, showing strong growth in net sales and profits, with substantial institutional interest.
Is Harrow, Inc. technically bullish or bearish?
As of September 8, 2025, Harrow, Inc. shows a bullish technical trend supported by positive MACD, Bollinger Bands, and moving averages, along with strong performance compared to the S&P 500.
Is Harrow, Inc. overvalued or undervalued?
Harrow, Inc. has shifted from a fair to a risky valuation grade due to being overvalued with significant losses, a troubling ROE of -37.99%, and high valuation ratios compared to peers, despite a strong stock performance over the past three years.
Harrow, Inc. Hits Day High with 8.63% Surge in Strong Intraday Performance
Harrow, Inc. has demonstrated impressive financial performance, with a significant year-over-year growth of 141.38% and a 33.27% increase in net sales. The company reported a pre-tax profit of USD 5 million, alongside strong institutional backing and a peak operating cash flow of USD 4.04 million.
Is Harrow, Inc. overvalued or undervalued?
Harrow, Inc. is currently overvalued with a risky valuation grade, reflected by a Price to Book Value of 19.24, an EV to EBITDA ratio of 58.98, and a negative ROE of -37.99%, contrasting sharply with peers like PetIQ, Inc. which has a fair valuation.
Is Harrow, Inc. technically bullish or bearish?
As of June 2, 2025, the trend is mildly bullish, supported by weekly MACD and KST indicators, while caution is advised due to mixed signals from daily moving averages.
Who are in the management team of Harrow, Inc.?
As of March 2022, the management team of Harrow, Inc. includes Dr. Robert Kammer (Independent Chairman), Mr. Mark Baum (CEO and Director), Dr. Richard Lindstrom (Director), Ms. Teresa Sparks (Independent Director), and Prof. R. Lawrence Van Horn (Independent Director).
What does Harrow, Inc. do?
Harrow, Inc. is a pharmaceutical company specializing in ophthalmology pharmaceutical compounding, with recent net sales of $48 million and a net profit of -$18 million. The company has a market cap of approximately $1.12 billion.
How big is Harrow, Inc.?
As of Jun 18, Harrow, Inc. has a market capitalization of 1,116.03 million, with net sales of 212.86 million and a net profit of -21.69 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
